Skip to search formSkip to main contentSkip to account menu

SF 1126

Known as: SF-1126, SF1126, pan-PI3K/mTOR Inhibitor SF1126 
A water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

ChromonesOligopeptides
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Our previous studies showed that the angiogenic… 
2012
2012
SF1126, a Pan-PI3K Inhibitor has Potent Pre-Clinical Activity in Aggressive B-Cell Non-Hodgkin Lymphomas by Inducing Cell Cycle Arrest and Apoptosis
The PI3K pathway is activated in a variety of human tumors including B-cell Non Hodgkin Lymphoma (B-NHL). Targeting this pathway… 
2011
2011
SF1126, a Pan-PI3K Inhibitor Has Superior Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-Hodgkin's Lymphoma
Abstract 2720 The PI3K pathway is constitutively active in B-cell non-Hodgkin lymphomas (B-NHL). PI3K pathway targeted therapies… 
2011
2011
Abstract LB-383: Translational studies of the novel prodrug PI3K/mTOR/PIM1 inhibitor SF1126 in DLBCL
Background : While selective inhibition of the δ PI3K isoform has demonstrated clinical efficacy in some B-cell malignancies… 
2010
2010
Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies.
Abstract 1783 Background: The PI3K/Akt/mTOR signaling pathway is an attractive target to inhibit for cancer therapy because it is… 
2010
2010
Abstract 337: In vitro evaluation of dual pan-PI3-kinase/mTOR inhibitor in HER2 overexpressing breast cancer cells
The HER/EGFR is a target of significant interest in human cancer due to the high frequency and broad spectrum aberrations in the… 
Review
2010
Review
2010
FDA Pipeline Preview, December 2010 (Ezogabine, Solesta, Dutasteride, Finasteride, Octaplex, SF1126, MP4CO, Ensituximab, Naloxone, CBLB502)
Recent FDA action (through, November 2010) related to Ezogabine, Solesta, Dutasteride, Finasteride, Octaplex, SF1126, MP4CO… 
2007
2007
Preclinical studies of a pan PI3K inhibitor (SF1126) in renal cell carcinoma
2378 The phosphatidylinositol 3-kinase /PTEN/AKT pathway is an important pathway that regulates a wide spectrum of tumor-related… 
2006
2006
A Vascular Targeted Pan PI-3 Kinase Inhibitor, SF1126 with Activity Against Multiple Myeloma In Vivo.
Background: Considerable evidence suggests an important role for the PI-3 kinase and AKT signaling pathways in survival and… 
2006
2006
Targeting PI3K in alveolar rhabdomyosarcoma (aRMS).
10025 Background: aRMS is a pediatric solid tumor with a poor prognosis despite aggressive therapy. HGF/c-Met & PTEN-PI3K-AKT… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)